RheumNow Podcast - Best of EULAR 2021
Jun 11, 2021
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Read Article
RA ILD: Stepping out of the shadows
Interstitial lung disease (ILD) is a common complication of rheumatoid arthritis (RA) with up to 8% of patients affected with clinically significant ILD.
https://t.co/BaoqQLKR5C https://t.co/duIqHVfCAa
Links:
Dr. John Cush @RheumNow( View Tweet )
Jun 17, 2021
Abatacept in RA ILD
Dr. Conway ( @RichardPAConway) discusses abstract POS0595 at the virtual #EULAR2021 meeting.
https://t.co/rpVuHOkS5w https://t.co/7pNzh6sb7a
Links:
Dr. John Cush @RheumNow( View Tweet )
Jun 15, 2021
RA ILD: Stepping out of the shadows
Jun 09, 2021
Despite being relatively common and frequently severe, RA-ILD has been a neglected area of research and indeed of clinical management in RA. In recent years we finally seem to have started making some progress in this area and this momentum has continued with a several interesting abstracts at
Read Article
Video: The Future of Treatment of RA-ILD: Dr. David Liew ( @drdavidliew )
Dr. David Liew reviews abstract OP0124 presented at #EULAR2021
https://t.co/0dqBPRiwjA https://t.co/XR7cQhPVRw
Links:
Dr. John Cush @RheumNow( View Tweet )
Jun 07, 2021
Clive Kelly presents data from INBUILD on nintedanib in progressive fibrosing RA-ILD over 52 weeks FVC decline -82.6 (41.3) mL in nintedanib vs -199.3 (36.2) mL in placebo (p=0.037) @RheumNow #EULAR2021 Abstr#OP0124 https://t.co/MZwzNoq6LC
Richard Conway @RichardPAConway( View Tweet )
Jun 06, 2021
Just a reminder: RA-ILD doesn't just happen in early disease; risk continues on long after diagnosis.
PS don't smoke if you have RA; smokers have an adj HR 1.92
PPS don't smoke if you don't want to get RA
PPPS don't smoke.
@MayoClinic POS0210 #EULAR2021 @RheumNow https://t.co/elhvJrK7B4
David Liew @drdavidliew( View Tweet )
Jun 04, 2021
Lots of discussion about RA-ILD, but what about bronchiectasis (BR) in RA? We found a pooled prevalence of RA-BR of 18.7% (some may have been subclinical). POS0522 Prevalence of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis #EULAR2021 @Janetbirdope
Jeffrey Sparks MD MMSc @jeffsparks( View Tweet )
Jun 04, 2021
Metabolomic profiling for PsA showed vLDL, triglycerides; apolipoprotein B, glycoprotein acetylene associated with increased CV events…
Do you monitor cholesterol levels in your PsA pts?
Abs#OP0221
#EULAR2021 @RheumNow
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 04, 2021
#EULAR2021 OP0290: Cluster analysis of APLS
4 Clusters:
⭐️ 2ndary APS, non-criteria
⭐️ ♂️ with CV risks
⭐️OB morbidity
⭐️Isolated LA +
@RheumNow
Eric Dein @ejdein1( View Tweet )
Jun 04, 2021
EULAR 2021 - Day 2 Podcasts
Jun 04, 2021
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
Read Article
Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021
https://t.co/S0ownscRKv https://t.co/PJODe0U6wr
Links:
Dr. John Cush @RheumNow( View Tweet )
Jun 04, 2021
New insights in RA-ILD therapeutics
Jun 04, 2021
RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to
Read Article
Dr Yoshida analyze data from US registry 40,721 RA patients. High 2.11 [1.13, 3.96] and moderate 1.97 [1.13, 3.43] CDAI associated w/ > HR of major adverse CV events. HRs decrease during follow up.
Tight and early disease control reduces CV burden!
#EULAR2021 @Rheumnow #OP0101 https://t.co/A0ZYE4v8uf
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 03, 2021
In 16,448 RA from ACR’s RISE registry: no difference in disease activity TNFi and non-TNFi at 12 months. Stratified analysis: ⬆️disease activity for TNFi vs. non TNFi in patients of Black and Asian ethnicity. To be confirmed in independent cohorts.
#EULAR2021 @Rheumnow #OP0117 https://t.co/7bFnOKR9uz
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 03, 2021
Can we predict pre-clinical RA-ILD?
@Juge_P_A ESPOIR cohort. model w/ 4 variables: male gender, older age @ diag, mean DAS-28 over follow-up and MUC5B variant ▶️ preclinical ILD after 13 years of RA w/ AUC=0.82 CI 95% (0.72-0.91) (Sens 80%, Spe 56%)
#POS0095 @Rheumnow #EULAR2021 https://t.co/bPyidNhNuO
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 03, 2021
Very informative #EULAR2021 WIN session on MIS-C @EULAR_org
👉 Steroids early
👉 IVIg in all
👉 anticoagulant use remains variable
#Coronary aneurysms
✅ occur during acute phase in MIS-C and improve with treatment
✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK
Ashima Makol MD @AshimaMakol( View Tweet )
Jun 03, 2021
Do we need to monitor #ECG in patients on #HCQ and #polypharmacy? Dr Antivalle reported ⬆️QTc interval in HCQ vs controls. Only 3/132 was above ULN in HCQ group though. Importantly,⬆️QTc was noted more in HCQ + co-meds (e.g. PPI) #EULAR2021 #POS0090 @RheumNow https://t.co/1Ui4MghqIk
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 03, 2021
How common is RA ILD? @RheumNow #EULAR2021 @eular_org
Janet Pope @Janetbirdope( View Tweet )
Jun 03, 2021
Leave my MTX alone says pt & #rheumatologist if pt has chronic ILD. Acute pneumonia from MTX is NOT chronic ILD in RA @RheumNow @eular_org #EULAR2021 #BoehringerIngelheim RA ILD silent killer symposium https://t.co/IQTINuUpVq
Janet Pope @Janetbirdope( View Tweet )
Jun 03, 2021
Turning the Corner on CV Risk in Rheumatoid Arthritis
Jun 03, 2021
Cardiovascular (CV) disease remains the leading cause of mortality in rheumatoid arthritis (RA). A number of studies progressed our knowledge in the session Rheumatoid arthritis - comorbidity and clinical aspects – I on Thursday at EULAR 2021.
Read Article
RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it esp if older pt #EULAR2021 #BoehringerIngelheim symposium @RheumNow @eular_org https://t.co/be2Z7KMqpg
Janet Pope @Janetbirdope( View Tweet )
Jun 03, 2021
MUC5B promoter variant is associated with interstitial lung disease.
Interactions with:
👉rheumatoid arthritis
👉 age
👉 sex
Check this Finnish biobank study of 250,000 individuals presented by Antti Palömaki at the Plenary Abstracts Session Wed 02/06 16:15
>LC
ARD & RMD Open @ARD_BMJ( View Tweet )
Jun 03, 2021
Dr Lam presenting data on early RA and matched controls. T2T strategy led to no increased CV event risk over 5 years. Longer remission duration protective, higher baseline HAQ associated with higher risk @RheumNow #EULAR2021 Abstr#OP0103 https://t.co/MZdEoyWI64
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2021
Using data of the E3N prospective observational study - including 98995 women - passive smoking in childhood or adulthood could be found as risk factor for #RA and potentially earlier onset
#OP0012 #EULAR2021 @RheumNow https://t.co/58DJ8lZzfV
Paul Studenic @Stiddyo( View Tweet )
Jun 02, 2021
Recent Blogs
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
Read Post
